Shares of Ginkgo Bioworks Holdings Inc. (DNA) plunged 12.63% in after-hours trading on Tuesday, following the release of the company's fourth quarter and full-year 2024 financial results. The biotechnology company reported a wider net loss and provided a disappointing revenue outlook for 2025, citing ongoing restructuring efforts and challenges in its Biosecurity segment.

The key factors contributing to Ginkgo Bioworks' after-hours slump are:
1. Weak 2025 Revenue Guidance: The company expects total revenue of $160-$180 million in 2025, lower than analysts' expectations, with its Biosecurity segment facing potential headwinds due to government funding availability.
2. Ongoing Restructuring Costs: Ginkgo incurred $24.2 million in restructuring charges in 2024, including employee termination costs and impairment of lease assets, as part of its plan to achieve cost reductions and reach profitability by 2026.
3. Tepid Biosecurity Performance: The Biosecurity segment reported a 51% year-over-year decline in revenue to $53 million in 2024, impacted by a transition from K-12 testing to a more recurring business model.